MatthewCFosterMD

PubMed

• 8 citations
  Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
  Daniel R. Richardson, Steven D. Green, Matthew C. Foster, Joshua F. Zeidner
  Current Hematologic Malignancy Reports. 2021-02-01
• 42 citations
  Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia.
  Joshua F. Zeidner, Benjamin G. Vincent, Anastasia Ivanova, Dominic T. Moore, Karen P. McKinnon
  Blood Cancer Discovery. 2021-09-10
• 77 citations
  Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute my...
  Joshua F. Zeidner, Matthew C. Foster, Amanda L. Blackford, Mark R. Litzow, Lawrence E. Morris
  Haematologica. 2015-09-01

Abstracts/Posters

• Oral Adherence in Adults with Acute Myeloid Leukemia: Results of a Mixed Methods Study
  Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart¬ Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients
  Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Final Clinical Results of a Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory AML
  Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (_6...
  Matthew C Foster, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Detection of Measurable Residual Disease (MRD) in Peripheral Blood: First Report of a Novel Microfluidic Platform in Patients with Acute Myeloid Leukemia (AML) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019